NZ701038A - Treating acute decompensated heart failure with relaxin - Google Patents

Treating acute decompensated heart failure with relaxin

Info

Publication number
NZ701038A
NZ701038A NZ701038A NZ70103809A NZ701038A NZ 701038 A NZ701038 A NZ 701038A NZ 701038 A NZ701038 A NZ 701038A NZ 70103809 A NZ70103809 A NZ 70103809A NZ 701038 A NZ701038 A NZ 701038A
Authority
NZ
New Zealand
Prior art keywords
heart failure
relaxin
treating acute
decompensated heart
acute decompensated
Prior art date
Application number
NZ701038A
Other languages
English (en)
Inventor
Martha Jo Whitehouse
Gad Cotter
Elaine Unemori
Sam L Teichman
Dennis R Stewart
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Priority claimed from NZ622598A external-priority patent/NZ622598A/en
Publication of NZ701038A publication Critical patent/NZ701038A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ701038A 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin NZ701038A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
NZ622598A NZ622598A (en) 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin

Publications (1)

Publication Number Publication Date
NZ701038A true NZ701038A (en) 2016-01-29

Family

ID=40834101

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ701038A NZ701038A (en) 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin
NZ589009A NZ589009A (en) 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with h2 relaxin
NZ598709A NZ598709A (en) 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ589009A NZ589009A (en) 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with h2 relaxin
NZ598709A NZ598709A (en) 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin

Country Status (30)

Country Link
US (7) US8053411B2 (https=)
EP (2) EP2288373B1 (https=)
JP (4) JP5651586B2 (https=)
CN (3) CN102036679A (https=)
AR (1) AR071810A1 (https=)
AU (1) AU2009246114B2 (https=)
BR (1) BRPI0913011A2 (https=)
CA (1) CA2724540C (https=)
CR (1) CR11749A (https=)
CY (1) CY1116925T1 (https=)
DK (1) DK2288373T3 (https=)
EA (2) EA201500552A1 (https=)
ES (1) ES2546287T3 (https=)
GB (2) GB2459983B (https=)
HK (1) HK1202054A1 (https=)
HR (1) HRP20150845T1 (https=)
HU (1) HUE025483T2 (https=)
IL (3) IL208992A (https=)
MA (1) MA32389B1 (https=)
MX (1) MX2010012450A (https=)
MY (2) MY159803A (https=)
NZ (3) NZ701038A (https=)
PL (1) PL2288373T3 (https=)
PT (1) PT2288373E (https=)
SG (2) SG191587A1 (https=)
SI (1) SI2288373T1 (https=)
TW (1) TWI386202B (https=)
UA (1) UA99953C2 (https=)
WO (1) WO2009140659A2 (https=)
ZA (1) ZA201007449B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520917A (ja) * 2008-05-16 2011-07-21 コーセラ，インコーポレーテッド 慢性心不全の治療方法
CN102036679A (zh) 2008-05-16 2011-04-27 科尔泰拉公司 用松弛素治疗与急性心力衰竭相关的呼吸困难
BR112012022654A2 (pt) * 2010-03-10 2016-11-01 Univ Florida modulação de aquaporinas com relaxina
EP2601532B1 (en) * 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2726502A1 (en) * 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CN108310396B (zh) * 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
WO2013165606A1 (en) 2012-05-04 2013-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of the relaxin receptor 1
UA117571C2 (uk) * 2012-10-26 2018-08-27 Чіесі Фармацеутічі С.П.А. Способи контролювання кров'яного тиску та зниження диспное при серцевій недостатності
MX367165B (es) 2013-04-05 2019-08-07 Scpharmaceuticals Inc Formulaciones farmacéuticas para administración subcutánea de furosemida.
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA2935628A1 (en) * 2014-02-03 2015-08-06 Novartis Ag Filters for infusion sets
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
CN106413740A (zh) * 2014-06-13 2017-02-15 诺华股份有限公司 用于降低gdf‑15的serelaxin应用
WO2017100540A2 (en) 2015-12-09 2017-06-15 The California Institute For Biomedical Research Relaxin immunoglobulin fusion proteins and methods of use
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
WO2020120482A1 (en) 2018-12-10 2020-06-18 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906019B1 (en) 2019-01-04 2025-11-26 SQ Innovation AG Pharmaceutical compositions of furosemide
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
EA202192129A1 (ru) 2019-01-31 2021-10-19 ЭсСиФАРМАСЬЮТИКАЛЗ ИНК. Концентрированные жидкие фармацевтические составы фуросемида и способы их введения
AU2023332056A1 (en) 2022-08-31 2025-03-13 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
EP0707650B1 (en) 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
CA2145515A1 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
EP0845992B1 (en) * 1995-08-15 2002-11-20 Connetics Corporation Use of relaxin for promoting angiogenesis
WO2001058468A1 (en) * 2000-02-09 2001-08-16 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
CN1968717B (zh) * 2004-03-30 2013-08-21 延世大学教产学协力团 含有松弛素基因的基因送递系统和使用松弛素的药物组合物
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
US8492329B2 (en) 2007-07-12 2013-07-23 Compugen Ltd. Bioactive peptides and methods of using same
JP2011520917A (ja) 2008-05-16 2011-07-21 コーセラ，インコーポレーテッド 慢性心不全の治療方法
CN102036679A (zh) * 2008-05-16 2011-04-27 科尔泰拉公司 用松弛素治疗与急性心力衰竭相关的呼吸困难

Also Published As

Publication number Publication date
WO2009140659A3 (en) 2010-07-22
IL208992A (en) 2013-09-30
AR071810A1 (es) 2010-07-14
SG10201609580YA (en) 2016-12-29
US20130116181A1 (en) 2013-05-09
HK1202054A1 (en) 2015-09-18
DK2288373T3 (en) 2015-09-28
US20120040902A1 (en) 2012-02-16
EP2829280A1 (en) 2015-01-28
EA201001771A1 (ru) 2011-06-30
MY159803A (en) 2017-02-15
JP2011520918A (ja) 2011-07-21
MX2010012450A (es) 2011-03-21
GB2459983A (en) 2009-11-18
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
SI2288373T1 (sl) 2015-12-31
CY1116925T1 (el) 2017-04-05
HK1151229A1 (en) 2012-01-27
CN106177914A (zh) 2016-12-07
US8415301B2 (en) 2013-04-09
EP2288373A2 (en) 2011-03-02
US8053411B2 (en) 2011-11-08
GB2459983B (en) 2010-04-28
US20100048475A1 (en) 2010-02-25
BRPI0913011A2 (pt) 2019-09-03
IL247351A0 (en) 2016-09-29
HK1140693A1 (en) 2010-10-22
US20150320834A1 (en) 2015-11-12
EP2288373B1 (en) 2015-06-24
PT2288373E (pt) 2015-10-19
CN103212063A (zh) 2013-07-24
AU2009246114A1 (en) 2009-11-19
US9205132B2 (en) 2015-12-08
US9066916B2 (en) 2015-06-30
IL208992A0 (en) 2011-01-31
PL2288373T3 (pl) 2015-11-30
SG191587A1 (en) 2013-07-31
HK1139051A1 (en) 2010-09-10
JP5875646B2 (ja) 2016-03-02
GB2462221A (en) 2010-02-03
HK1187550A1 (zh) 2014-04-11
GB0918132D0 (en) 2009-12-02
JP2016053040A (ja) 2016-04-14
EA201500552A1 (ru) 2016-07-29
US9579363B2 (en) 2017-02-28
US20130210730A1 (en) 2013-08-15
ES2546287T3 (es) 2015-09-22
HRP20150845T1 (hr) 2015-11-06
JP5638044B2 (ja) 2014-12-10
CA2724540A1 (en) 2009-11-19
IL228244A (en) 2016-10-31
JP2015013870A (ja) 2015-01-22
GB0908432D0 (en) 2009-06-24
US20120040903A1 (en) 2012-02-16
HUE025483T2 (en) 2016-02-29
TWI386202B (zh) 2013-02-21
JP5651586B2 (ja) 2015-01-14
CN103212063B (zh) 2015-07-22
WO2009140659A2 (en) 2009-11-19
MY158327A (en) 2016-09-30
ZA201007449B (en) 2011-06-29
CA2724540C (en) 2014-07-08
GB2462221B (en) 2010-09-01
NZ598709A (en) 2013-09-27
AU2009246114B2 (en) 2013-01-31
EA022948B1 (ru) 2016-03-31
TW200948353A (en) 2009-12-01
UA99953C2 (uk) 2012-10-25
CN102036679A (zh) 2011-04-27
US8372809B2 (en) 2013-02-12
CR11749A (es) 2011-02-11
JP2013040174A (ja) 2013-02-28
US20170151311A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
NZ701038A (en) Treating acute decompensated heart failure with relaxin
ZA201104600B (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
NZ588033A (en) Methods of treating a mif-mediated disorder
PL3338791T3 (pl) Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
NZ602798A (en) Treatment of sarcoidosis using placental stem cells
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
WO2009065093A3 (en) Use of stem cells for wound healing
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
EP2063902A4 (en) THERAPEUTIC CELL MEDICAMENT WITH STEM CELLS OF SKIN
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
TR201900240T4 (tr) Gece idrara çıkışları azaltmak için desmopresin.
EA201170873A1 (ru) Безопасное введение десмопрессина
IL205675A0 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
IL215460A (en) Use of vip-containing compositions for the manufacture of medications for the prevention or treatment of osteoporosis and diarrhea
MX2010011401A (es) Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica.
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
NZ622598A (en) Treating acute decompensated heart failure with relaxin
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
IL216984A0 (en) Cloning, yeast expression, purification and biological activity of the extension region of the soybean 7s globulin alfa' subunit involved in hep g2 cell cholesterol homeostasis
贾雪 et al. The Effect of Comprehensive Rehabilitation System on the Treatment of 54 Earthquake Patients with Lower Limb Fracture

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 MAY 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20160512

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAY 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20160512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAY 2018 BY CPA GLOBAL

Effective date: 20170418

LAPS Patent lapsed